SCHEMBL6097463

SCHEMBL6097463

COc1ccc(NC(=S)Nc2ccccc2Cc2ccc3[nH]c(=O)cc(C(F)(F)F)c3c2)c(C)c1

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.45
MAPT P10636 3/20 0.45
LMNA P02545 3/20 0.45
HTT P42858 2/20 0.45
ALOX12 P18054 2/20 0.45
ALDH1A1 P00352 2/20 0.43
AR P10275 7/20 0.40
GAA P10253 3/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
RAB9A P51151 1/20 0.39
HPGD P15428 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6097863 0.90 ALDH1A1 (0.56) LMNAALDH1A1ARGAAMEN1
SCHEMBL6097336 0.88 HTT (0.50) SMN1; SMN2MAPTLMNAHTTALOX12
SCHEMBL6097122 0.83 AR (0.44) MAPTLMNAALDH1A1ARKMT2A
SCHEMBL6095932 0.81 ALOX12 (0.47) SMN1; SMN2MAPTLMNAHTTALOX12
SCHEMBL6095919 0.81 AR (0.45) MAPTLMNAALDH1A1ARHPGD
SCHEMBL6095079 0.81 AR (0.43) MAPTLMNAHTTALDH1A1AR
SCHEMBL6110711 0.81 AR (0.46) AR
SCHEMBL6094713 0.80 QPCT (0.42) SMN1; SMN2MAPTLMNAALOX12ALDH1A1
SCHEMBL6110773 0.79 AR (0.49) AR
SCHEMBL6098331 0.79 KDM4E (0.46) SMN1; SMN2MAPTLMNAHTTALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115745-B2 Benzyl urea and thiourea derivatives WARNER LAMBERT COMPANY LLC (US) 2006-10-03 US claimed
EP-1597233-A1 BENZYL UREA AND THIOUREA DERIVATIVES USEFUL AS ANDROGEN ANTAGONISTS Warner-Lambert Company LLC (US) 2005-11-23 EP claimed
WO-2004072043-A1 BENZYL UREA AND THIOUREA DERIVATIVES USEFUL AS ANDROGEN ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-08-26 WO claimed
US-7115745-B2 Benzyl urea and thiourea derivatives WARNER LAMBERT COMPANY LLC (US) 2006-10-03 US disclosed
EP-1597233-A1 BENZYL UREA AND THIOUREA DERIVATIVES USEFUL AS ANDROGEN ANTAGONISTS Warner-Lambert Company LLC (US) 2005-11-23 EP disclosed
US-20050107427-A1 Benzyl urea and thiourea derivatives DU DANIEL Y (US) 2005-05-19 US disclosed
WO-2004072043-A1 BENZYL UREA AND THIOUREA DERIVATIVES USEFUL AS ANDROGEN ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107427-A1 Benzyl urea and thiourea derivatives BRDT, TAS2R8, FSHR SMN1; SMN2 4881/4885MAPT 4365/4885LMNA 4794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.